Foundation Medicine Launches FoundationOne®MRD, First-of-Its-Kind Molecular Residual Disease Test to Combine Structural Variants and Digital PCR
Enables ultra-sensitive molecular disease detection, with high specificity
Provides accelerated results, with the personalized tumor fingerprint and initial blood test expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results anticipated within 1 to 3 days
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the launch of FoundationOne®MRD, a molecular residual disease (MRD) test.1 This launch follows the completion of Roche’s acquisition of SAGA Diagnostics. FoundationOne MRD is the first-of-its-kind MRD test to combine structural variants and digital PCR, enabling ultra-sensitive MRD detection, with high specificity.2
FoundationOne MRD leverages a differentiated approach designed to deliver highly sensitive and specific MRD detection alongside an accelerated turnaround time for healthcare providers. The personalized tumor fingerprint and initial blood test can be expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results can be anticipated within 1 to 3 days. This new MRD offering is covered by Medicare for cancer recurrence monitoring in early-stage breast cancer across all subtypes, with plans for a global launch.3
